Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.

C MartineauB FlouriéP WilsT VaysseR AltweggAnthony BuissonA AmiotG Pineton de ChambrunV AbitbolM FumeryX HébuterneS ViennotD LaharieL BeaugerieS NanceyH Sokolnull null

Published in: Alimentary pharmacology & therapeutics (2017)

After failure of infliximab or adalimumab for Crohn's disease, golimumab was safe and seemed beneficial in half of the patients.